Loading
A phase 3 trial of Olomorasib, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06119581 by Eli Lilly and Company, with 1264 participants planned, started 2023-12-21 and due to reach its primary completion in 2027-11. Interventions recorded: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin and Pemetrexed.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.